Fate Therapeutics (FATE) Cash from Financing Activities (2012 - 2025)

Fate Therapeutics (FATE) has 14 years of Cash from Financing Activities data on file, last reported at $1.7 million in Q4 2025.

• Quarterly Cash from Financing Activities fell 46.01% year-over-year to $1.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.5 million (down 94.5% YoY) and the FY2025 annual result came in at $5.5 million, down 94.5% from the prior year.
• Cash from Financing Activities declined to $1.7 million in Q4 2025, from $2.5 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $438.0 million in Q1 2021 to a low of -$180000.0 in Q4 2023.
• A 5-year average of $33.4 million and a median of $2.5 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities sank 111.87% — and 2024, when it surged 46029.47%.
• Tracing FATE's Cash from Financing Activities over 5 years: stood at $3.4 million in 2021, then plunged by 55.62% to $1.5 million in 2022, then slumped by 111.87% to -$180000.0 in 2023, then jumped by 1838.89% to $3.1 million in 2024, then tumbled by 46.01% to $1.7 million in 2025.
• The last three Cash from Financing Activities figures came in at $1.7 million (Q4 2025), $2.5 million (Q3 2025), and $1.3 million (Q2 2025), per Business Quant data.